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economics and social security were extracted. The burden was measured for “LBP-
episodes”, defined as time periods with consecutive visits to the healthcare system 
with a relevant diagnosis code, continuing until 6 months have elapsed without 
costs incurred by LBP-related visits. Results: More than 72,000 patients were iden-
tified, with over 95,000 LBP-episodes. The average episode length was 56/176 days in 
episodes without/with surgery. The mean total cost per episode was estimated at 
€ 5,453, where indirect costs constituted 68.4%, medical visits including diagnostic 
imaging 14.5%, other inpatient care 8.2%, surgery 7.9%, and pharmaceuticals 1.0%. 
In men/women, the mean total cost per episode was estimated to € 22,174/€ 24,833 
in episodes with surgery, and € 4,175/€ 3,957 in episodes without surgery. The total 
burden of LBP in Sweden in 2012 was estimated at € 704M, with a burden per capita 
of € 73. Higher age, women, comorbidities, surgery and less education were found 
to be significant predictors of higher costs. ConClusions: The societal burden of 
LBP is substantial and varies significantly between different types of patients. It 
is important to identify periods and interventions within a LBP-episode that can 
be relevantly adjusted in order to optimize cost-effectiveness of treatment, and 
also, to realize that results may be dependent on the time frame chosen for a LBP-
episode. Acknowledgements: The study was financed with an unrestricted grant 
from Medtronic.
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objeCtives: The aim of this study was to calculate the years of working life lost 
(YWLL) from early exit from work associated with Osteoarthritis (OA). Methods: 
We used data from the population-based EpiReumaPt study (Sep2011-Dec2013). 
10,661 inhabitants were surveyed to capture all cases of RD within a representa-
tive sample of the Portuguese population. We analyzed all aged 50-65 years old 
(yo), near the official retirement age. YWLL were determined for OA cases with 
premature exit from work caused by RD (self-reported) estimated as the difference 
between each participant’s age and the respective age (“observed stock”), while the 
potential YWLL (PYWLL: YWLL+“expected stock” of YWLL still to occur if there is 
no return-to-work) was the difference between official and actual retirement ages. 
We also calculated the percentage of time in inactivity (inactivity ratio= YWLL/
Active age-range[15-65yo]). We excluded all OA participants with concomitant 
inflammatory rheumatic diseases with possible impact on retirement, such as 
rheumatoid arthritis and spondylarthritis. All cases with retirement prior to 
onset of OA symptoms were also excluded. All results were based on weighted 
data. Results: The estimated prevalence of OA in the Portuguese population 
(50-64 yo) is 29.7% (knee:18.6%; hand:12.6%; hip:3.6%). Among these, 61.8% were 
out of work versus 47.6% for those without OA (p= 0.004), which potentially led to 
162,735 YWLL (95 per 1000 inhabitants). Early retirement contributed the most for 
these YWLL (58%; 94,432 YWLL), followed by unemployment (35%; 57,209 YWLL) 
and disability pensions (7%; 11,094 YWLL). Women accounted for 80% of these 
YWLL (153 per 1000 female inhabitants). A total of 161,621 PYWLL were estimated 
if early retirement is considered and 369,839 PYWLL for all forms of exit from 
work. The mean YWLL and PYWLL inactivity ratios were 16% and 30%, respec-
tively. ConClusions: We estimated a considerable amount of working life years 
losses associated with OA in Portugal.
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objeCtives: To estimate the economic burden of hip fractures in Norway under 
different assumptions on the future demographic and fracture rate develop-
ment. Methods: Based on population projections from Statistics Norway and 
estimated fracture rates, we projected the future number of hip fractures in the 
period 2014-2040. We projected assuming both a low, medium and high population 
increase. We estimated fracture rates based on data from the hip fracture database 
of the Norwegian Epidemiologic Osteoporosis Studies (NOREPOS), using data for 
the period 1999 to 2008. We predicted future fracture rates under three scenarios: 
assuming a constant future rate, assuming a continued decline in the fracture 
rate and assuming a continued, but somewhat reduced decline. We considered 
a medium population growth and a reduced decline as the most likely scenario. 
To the estimated number of fractures we added the cost of hip fracture surgery 
and other health and social care cost related to hip fractures from a recent Lancet 
publication. Results: The projected future cost in the period from 2014 to 2040 
varies from a 14% increase in the best-case scenario to 121% increase in cost in 
the worst-case scenario, with a 65% increase as the most likely estimate. From 
a hospital perspective, the costs could increase from € 108M to either € 119M in a 
best-case scenario or € 235M in a worst-case scenario. If we include not only the 
cost of the primary hospitalization, but also the cost of other health and social 
services (e.g. long term nuring home care) related to the fracture, the cost impact 
will increase from € 341M to € 388M either or € 766M ConClusions: Our study 
indicates that the number and cost of hip fractures is likely to increase until 2040, 
but the magnitude of the impact is very much dependent on demographic change 
and fracture rate development.
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mean age of 65.9 (±10.5) years, 62.1% female, and 88.2% retired. Annual mean 
all-cause cost was $2,466 per patient with osteoporosis-related cost accounting 
for 53.8%. For osteoporosis-related health services, 33.2% of patients experienced 
≥ 1 hospitalization with mean length of stay of 18.0 (±14.4) days and mean cost of 
$2,913 per admission, and 83.2% of patients experienced ≥ 1 outpatient visit with 
mean (±SD) number of visits 7.4 (±8.7) and mean cost $17 per visit. The medical 
device cost was the largest component (38.5%) of osteoporosis-related cost, fol-
lowed by drug cost (31.1%) and examination cost (11.7%). The regression model 
revealed that osteoporosis-related cost tended to increase with age, patients with 
hip, vertebral, lower leg and multiple fractures were more likely to have a higher 
cost. ConClusions: Costs for patients with osteoporotic fractures were consid-
erable in Tianjin China, driven mainly by osteoporosis-related hospitalizations. 
Efforts focused on reducing the utilization of inpatient services and increasing 
efforts to lower the fracture risks may have the potential to lighten the economic 
burden of osteoporotic fractures in China.
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objeCtives: The aim of this study was to assess the indirect costs caused by 
absenteeism associated with ankylosing spondylitis (AS) from the perspective of 
the Social Insurance Institution (ZUS) in Poland. Methods: The estimates were 
based on data from the year 2013 concerning absence from work due to the ill-
ness (sick leave) the amount of short-term disability, the sufferers of which claim 
rehabilitation benefit, and the amount of long-term disability (permanent or fixed 
time), the sufferers of which claim disability pension. Costs were calculated taking 
into account Gross Domestic Product (GDP) per capita equaled € 10 278, Gross Value 
Added (GVA) per worker equaled € 24 680 and Gross Income (GI) per worker equaled 
€ 7 339 were presented in 2013 prices. Results: Total indirect costs of AS in the year 
2013 calculated using GDP per capita, GVA and GI per worker in Poland were € 24 416 
394, € 58 631 008 and € 17 435 690, respectively. The highest component of indirect 
costs of AS was permanent long-term disability (68%). Sick leave and short-term 
disability costs constitute 12% and 4% of total indirect costs of AS, respectively. In 
2013 Poland’s Social Insurance Institution database reported 3 400 patients that 
had 7 137 sick leave episodes, 225 short-term disability episodes and 198 long-term 
disability episodes. Indirect costs per patient associated with sick leave were € 894, 
€ 2 147 and € 639 calculated using GDP, GVA and GI, respectively. Indirect costs per 
patient associated with short-term disability were € 259, € 622 and € 185 respectively 
and associated with long-term disability were as high as € 6 028, € 14 474 and € 4 304, 
respectively. ConClusions: AS in Poland generated high indirect costs. The main 
component was permanent long-term disability; short-term disability generated 
lower costs of lost productivity. The highest cost per patient was generated by per-
manent long-term disability.
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objeCtives: Chronic Inflammatory Rheumatic Diseases (CIRD), especially 
Rheumatoid Arthrits and Spondyloarthritis, are systemic inflammatory disorders 
significantly affecting patients’ quality of life. Disability and comorbidity associ-
ated to such conditions trigger high costs for healthcare systems and society. This 
analysis aims to measure direct costs in patients receiving pharmacological treat-
ment. Methods: Using administrative healthcare claims from the Piedmont region 
in the North-West of Italy, we detected CIRD patients who, during the period Jan 2008 
- Dec 2010, had > 1 disease-modifying antirheumatic drug (DMARD) prescription, 
either synthetic (e.g. methotrexate) or biologic (e.g. infliximab). RD was confirmed if 
patients had > 1 hospital diagnosis of CIRD (rheumatoid arthritis, psoriatic arthritis, 
ankylosing spondylitis, ICD-9 codes : 714.0, 696.0, 720.0) and/or an exemption code 
for similar diagnoses. Each patient was followed up from first DMARD prescription 
(index date) for three years or until death. Results: In the selected period N= 12,455 
patients with CIRD diagnosis received DMARD. Patients were mainly female (58.1%), 
with a mean age of 55.3 (+17.4) years. Direct annual costs were € 6,983, € 4,974, € 5,178, 
during Year 1, 2, 3. The composition of average annual costs was: € 1,531 (26.8%) 
for hospital costs and emergency room costs, € 163 (2.9%) for synthetic DMARDs, 
€ 2,188 (38.3%) for biologic DMARDs, € 985 (17.2%) for concomitant medications, € 845 
(14.8%) for ambulatory visits. N= 4,670 (37.5%) received biologic therapy during the 
follow-up. ConClusions: Chronic Inflammatory Rheumatic Diseases determine 
a relevant economic burden for healthcare services, because of significant epide-
miological impact and high per-patient costs. Costs are significantly high at every 
stage of disease, both at time of diagnosis, and over time.
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objeCtives: The objective of this study was to estimate the direct and indirect 
costs of low back pain with/without radiant pain (LBP) in Sweden using the concept 
of “LBP-episode”, and to identify the variation of these across different patients 
groups. Methods: Patients visiting healthcare providers, or receiving health insur-
ance benefits, with a LBP-diagnosis in the region of Västra Götaland in 2008-2012 
were identified in the administrative database VEGA. Data from additional Swedish 
national registers including inpatient and outpatient care, drug prescriptions, socio-
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objeCtives: Determine the persistence, clinic and economic impact of Etanercept 
(ETN) y Adalimumab (ADA) reduced dose in Rheumatoid Arthritis (RA), Psoriatic 
Arthropathy (PA) and Ankylosing Spondylitis (AS) Patients with at least 1 year in 
Clinical Remission Methods: Observational, retrospective cohort of patients in off-
label program receiving ETN or ADA at reduced dose for at least 6 months (Jan2010 
to Dec2014). Inclusion Criteria: patients treated with ETN or ADA at standard dose 
that achieve and maintain clinical remission (DAS28< 2.6 or BASDAI< 2) during at 
least 1 year were selected to reduce their standard dose.We collected age, sex, indi-
cation, persistence of ETN or ADA at reduced dose during the study period. In these 
patients, we simulated the cost of treatment with ETN or ADA as if they had received 
ETN or ADA at standard dose during their ETN or ADA at reduced dose respec-
tive periods. Economic impact was assessed using Enbrel® and Humira® Spanish 
official prices. Results: From Jan2010 to Dec2014, 144 patients (51% women; age 
51±9 years; 75 RA, 37 PA, 32 AS) received ETN or ADA at reduced dose for at least 0.5 
years. 80 (56%) patients received ETN reduced dose and 64 (44%) patients received 
ADA reduced dose. Patients with ETN reduced dose presented a persistence of 
2,71±1,37years (AR 2,64±1,54, AP 2,56±0,80 y EA 3,04±1,31) and with ADA reduced 
dose presented a persistence of 2,07±0,96years (AR 2,37±0,92, AP 1,86±0,73y EA 
1,74±0,81). Total cost of this low dose strategy throughout the observation period 
were 1.485.510€ . If these patients had been treated with ETN or ADA standard dose, 
the total cost of therapy would have been 2.971.020€ . The implementation of the 
optimized therapy of ETN or ADA saved 1.485.510€ . ConClusions: Reducing the 
dosage of ETN and ADA in selected patients could make treatment more cost-effec-
tive and allow physicians to treat more patients with a fixed budget.
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objeCtives: The aim of this study was to explore the treatment protocol of Systemic 
Juvenile Idiopathic Arthritis (SJIA) in Turkey and to assess the impact of pricing and 
reimbursement policies on the treatment budget of SJIA. Methods: Delphi panel 
method was used in the study. First, a group of rheumatologists answered the Delphi 
panel questionnaire, designed to explore the type and frequency of resources used 
in treatment of SJIA. This was followed by a consensus-building meeting. Budget 
impact was determined by using the Social Security Institution’s related guide-
lines Results: Treatment of SJIA starts with NSAIDs, followed by glucocorticoids 
and DMARDS. Then approximately 40% of the patients, who has not answered the 
agents stated above, continue treatment with biologic agents including anti-TNF 
agents (etanercept, infliksimab, adalimumab), IL-1 (canakinumab) or IL-6 inhibitors 
(tocilizumab). ConClusions: Biologic agents had the largest share in total treatment 
costs mainly because of their relatively higher prices. Some biologics are imported 
from abroad through Turkish Pharma Association as they are not included in posi-
tive list by the Social Security Institution (SSI) yet, adding to the high cost dilemma.
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objeCtives: To analyze the changes in pharmacotherapy and their impact on 
costs for 2 years period for patients with rheumatoid arthritis (RA). Methods: 
The study is retrospective regarding to the cost for the last 1 year (May 2013 - May 
2014) and prospective regarding to the costs for the current therapy (May 2014-May 
2015). It is conducted in all clinical centers that periodically examine chronic RA 
patients. Bottom-up approach was applied using data from the patients’ records 
during their last visit to specialists in the clinical centers. Results: A total 11.83% 
men and 88.17% women with RA were observed. In the age group 51-60 years are 
32.26% of all patients and in the age group over 60 years are 24.73%. 31 patients 
were transferred to biological therapy during their last examination. The average 
RA pharmacotherapy monthly costs for biological drugs, NSAIDs, disease-modifying 
drugs, p.o. corticosteroids and parenteral corticosteroids for 1 year and from now 
on are: 763.60 (SD 296.90) vs. 890.62 (SD 134.58), 5.10 (SD 4.74) vs. 3.54 (SD 3.43), 5.37 
(SD 5.53) vs. 3.40 (SD 4.01), 3.30 (SD 1.40) vs. 2.59 (SD 1.15), 0.37 (SD 0.70) vs. 1.21 
(SD 2.27), respectively. The costs increased significantly (p> 0.05) when biological 
medicines and parenteral corticosteroids started to be prescribed, and decreased for 
the other therapeutic groups mostly due to price revision or new generics entrance. 
Combination of disease-modifying rheumatoid agents (DMRA) and biological treat-
ment is prescribed to 35.5% of the 31 patients on biological therapy. ConClusions: 
The variations in the pharmacotherapy costs are due to wide differences in therapy 
regimes and significantly high costs for biological therapy. Biological treatment 
consumes a significant financial resources but it is an inevitable option especially 
for patients with no effect from disease-modifying drugs.
objeCtives: The aim of this study was to assess the disease activity as well as 
indirect costs associated to absenteeism and presenteeism generated by patients 
with ankylosing spondylitis (AS) in a Polish population. Methods: On-line ques-
tionnaire survey was performed to obtain data on disease activity and the quality 
of life. We used Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) with 
additional questions about days missed from work (absenteeism) and decrease of 
on-the-job productivity (presenteeism). BASDAI score was obtained using on-line 
calculator. Total indirect costs were estimated with the Human Capital Approach 
using gross domestic product (GDP) per capita equaled € 10,774 and gross value 
added (GVA) per worker equaled € 25,838. Costs were expressed in 2014 euro. The 
Spearman’s correlation was used to present the association between the disease 
activity and the indirect costs. Results: Total 66 questionnaires were obtained. 
Patients reported mostly the problems with general discomfort and morning stiff-
ness represented by 8 points on BASDAI scale, followed by tiredness and neck pain 
represented by 7 points and other pain represented by 5 points. Almost 30% of 
patients reported that morning stiffness lasts longer than two hours. The mean 
BASDAI score was 5.87 (SD: 1.81). Of all patients 62% were working. Mean number 
of days missed from work was 41 a year (SD: 94) generating indirect cost of € 1,197 
(SD: € 2,776) calculated using GDP per capita and € 2,871 (SD: € 6,657) calculated 
using GVA per worker. Mean decrease of on-the-job productivity was 49% (SD: 24%) 
which was responsible for € 5,287 (SD: € 2,552) and € 12,678 (SD: € 6,120) of indirect 
costs, calculated using GDP per capita and GVA per worker, respectively. Disease 
activity was significantly correlated with indirect costs generated by absenteeism 
(0.271) and presenteeism (0.715). ConClusions: AS is a disease that generates 
huge economic burden. Study revealed that indirect costs are associated with 
the disease activity.
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objeCtives: To provide an estimation of expected lifetime numbers, risks, and bur-
den of fractures for 50-year old Chinese women. Methods: A discrete event simu-
lation model was developed to simulate the lifetime fractures of 50-year old Chinese 
women at the average risk of osteoporotic fractures. Main events in the model 
included hip fracture, vertebral fracture, wrist fracture, humerus fracture, and other 
fracture. Input fracture risks were calculated with the FRAX® tool and the declin-
ing exponential approximation of life expectancy (DEALE) approach. Simulations 
of 50-year old Chinese women without fracture risks were also carried out to 
determine the burden of fractures. Results: For a 50-year old Chinese woman 
at the average risk of fractures, there are 0.135 (95% CI: 0.134-0.137) hip fractures, 
0.120 (95% CI: 0.119-0.122) vertebral fractures, 0.095 (95% CI: 0.094-0.096) wrist frac-
tures, 0.079 (95% CI: 0.078-0.080) humerus fractures, and 0.407 (95% CI: 0.404-0.410) 
other fractures expected for the rest of her life. The residual lifetime risks of any 
fracture, hip fracture, vertebral fracture, wrist fracture, humerus fracture, and other 
fracture for a 50-year old Chinese woman are 37.36%, 11.77%, 10.47%, 8.61%, 7.30%, 
and 27.80%, respectively. The fracture-attributable excess quality-adjusted life year 
(QALY) loss and lifetime costs are estimated at 0.11 QALYs (95% CI: 0.00-0.22 QALYs) 
and US$714.61 (95% CI: US$709.20-720.02), totaling to a net monetary benefit loss 
of US$1,104.43 (95% CI: US$904.09-1,304.78). ConClusions: Chinese women at 
the age of 50 years old are at a high risk of any osteoporotic fracture. The expected 
economic and quality of life burden attributable to fractures among Chinese women 
is substantial.
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objeCtives: No adequate data are available about the epidemiology of spinal 
fusion surgery and its economic impact. The objective of this analysis was to 
assess the epidemiologic and economic burden of arthrodesis from a large popula-
tion based-study. Methods: Lombardy Region includes around 9.9 million indi-
viduals. The study population was identified through a data warehouse (DENALI), 
which matches with a probabilistic linkage demographic, clinical and economic 
data of different Healthcare Administrative databases. The study population was 
made by all subjects who, during the period January 2001–December 2010, under-
went a spinal fusion surgery identified by one of the following codes ICD9-CM: 
81.04 81.05, 81.06, 81.07 and 81.08. The first procedure was used as index event. We 
estimated the incidence of first spinal fusion surgery, the population and surgery 
characteristics and the healthcare costs from the National Health Service’s per-
spective. Results: During the study period, 17,772 (53.2% female) spinal fusion 
surgeries were detected. The results showed an increasing patients’ average age 
during the time period considered. The incidence rate of interventions increased 
from 12.6 to 19.1 per 100,000 person-year in the observational period between 
2001 and 2006. During the last 4 years of observation, the incidence was above 
20.0 per 100,000 person-year. The average hospital length of stay reported for the 
index event was 17.1 days in the 2001 and decreased until 11.0 days in the 2004. 
The average cost of the spinal fusion surgery increased during the observational 
period, from € 4.381 up to € 9,388. ConClusions: The study showed an increas-
ing incidence of spinal fusion surgery and costs from 2001 to 2010 in the Italian 
Lombardy Region. These results can be used to better understand the epidemio-
logical and economic burden of these types of interventions, and help to optimize 
the resources available considering the different surgical procedures available 
today.
